María E. Rodríguez-Ruiz

10.0k total citations · 6 hit papers
89 papers, 6.3k citations indexed

About

María E. Rodríguez-Ruiz is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, María E. Rodríguez-Ruiz has authored 89 papers receiving a total of 6.3k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Oncology, 54 papers in Immunology and 14 papers in Molecular Biology. Recurrent topics in María E. Rodríguez-Ruiz's work include Immunotherapy and Immune Responses (41 papers), Cancer Immunotherapy and Biomarkers (39 papers) and CAR-T cell therapy research (19 papers). María E. Rodríguez-Ruiz is often cited by papers focused on Immunotherapy and Immune Responses (41 papers), Cancer Immunotherapy and Biomarkers (39 papers) and CAR-T cell therapy research (19 papers). María E. Rodríguez-Ruiz collaborates with scholars based in Spain, United States and Switzerland. María E. Rodríguez-Ruiz's co-authors include Ignacio Melero, José Luis Perez‐Gracia, Miguel F. Sanmamed, Pedro Berraondo, Mariano Ponz‐Sarvisé, M. Ángela Aznar, Alfonso R. Sánchez-Paulete, Sandra Demaria, María C. Ochoa and Eduardo Castañón and has published in prestigious journals such as Nature, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

María E. Rodríguez-Ruiz

88 papers receiving 6.3k citations

Hit Papers

Cytokines in clinical cancer immunotherapy 2018 2026 2020 2023 2018 2019 2018 2019 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cytokines in clinical cancer immunotherapy
    2018 855 citations Pedro Berraondo, Miguel F. Sanmamed et al. profile →
  2. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
    2019 449 citations Kurt A. Schalper, María E. Rodríguez-Ruiz et al. profile →
  3. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect
    2018 356 citations María E. Rodríguez-Ruiz, Ignacio Melero et al. profile →
  4. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
    2019 323 citations Luna Minute, Itziar Otano et al. profile →
  5. Paradigms on Immunotherapy Combinations with Chemotherapy
    2021 278 citations Diego Salas‐Benito, José Luis Perez‐Gracia et al. Cancer Discovery profile →
  6. Cross-priming in cancer immunology and immunotherapy
    2025 33 citations Carlos Luri‐Rey, Álvaro Teijeira et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
María E. Rodríguez-Ruiz Spain 34 4.0k 3.6k 1.3k 880 616 89 6.3k
Liufu Deng China 22 4.0k 1.0× 4.5k 1.3× 1.8k 1.3× 1.2k 1.4× 500 0.8× 34 7.3k
Miguel F. Sanmamed Spain 40 5.6k 1.4× 5.0k 1.4× 2.5k 1.9× 1.5k 1.7× 751 1.2× 115 9.3k
Claire Vanpouille‐Box United States 30 3.2k 0.8× 2.7k 0.7× 1.3k 1.0× 1.1k 1.3× 491 0.8× 68 5.4k
Jitka Fučíková Czechia 37 2.8k 0.7× 3.6k 1.0× 1.5k 1.1× 637 0.7× 767 1.2× 70 5.6k
Junzo Hamanishi Japan 33 4.4k 1.1× 3.6k 1.0× 1.7k 1.2× 965 1.1× 248 0.4× 142 7.4k
Ferdy J. Lejeune Switzerland 44 3.3k 0.8× 3.2k 0.9× 2.6k 2.0× 1.0k 1.2× 435 0.7× 119 7.3k
Mark P. Chao United States 31 2.6k 0.6× 5.3k 1.5× 2.7k 2.0× 327 0.4× 539 0.9× 73 8.5k
Gunnar Kvalheim Norway 43 2.9k 0.7× 1.8k 0.5× 1.7k 1.2× 571 0.6× 311 0.5× 173 5.5k
Sebastian Kobold Germany 36 3.3k 0.8× 2.7k 0.7× 1.7k 1.3× 353 0.4× 775 1.3× 141 5.5k
Sumit K. Subudhi United States 37 4.0k 1.0× 3.6k 1.0× 1.5k 1.1× 1.8k 2.0× 215 0.3× 108 7.3k

Countries citing papers authored by María E. Rodríguez-Ruiz

Since Specialization
Citations

This map shows the geographic impact of María E. Rodríguez-Ruiz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by María E. Rodríguez-Ruiz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites María E. Rodríguez-Ruiz more than expected).

Fields of papers citing papers by María E. Rodríguez-Ruiz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by María E. Rodríguez-Ruiz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by María E. Rodríguez-Ruiz. The network helps show where María E. Rodríguez-Ruiz may publish in the future.

Co-authorship network of co-authors of María E. Rodríguez-Ruiz

This figure shows the co-authorship network connecting the top 25 collaborators of María E. Rodríguez-Ruiz. A scholar is included among the top collaborators of María E. Rodríguez-Ruiz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with María E. Rodríguez-Ruiz. María E. Rodríguez-Ruiz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luri‐Rey, Carlos, Álvaro Teijeira, Stefanie K. Wculek, et al.. (2025). Cross-priming in cancer immunology and immunotherapy. Nature reviews. Cancer. 25(4). 249–273. 33 indexed citations breakdown →
2.
Segura‐Collar, Berta, Diego Megı́as, Carlos E. de Andrea, et al.. (2024). NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. Journal for ImmunoTherapy of Cancer. 12(8). e009210–e009210. 5 indexed citations
3.
Melero, Ignacio, Maria J. de Miguel, Guillermo de Velasco, et al.. (2024). Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.. Journal of Clinical Oncology. 42(16_suppl). 2513–2513. 2 indexed citations
4.
Steeghs, Neeltje, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, et al.. (2024). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical Cancer Research. 30(13). 2693–2701. 11 indexed citations
5.
Rodríguez-Ruiz, María E., Paloma Sánchez‐Mateos, Maite Álvarez, et al.. (2023). Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control. Journal for ImmunoTherapy of Cancer. 11(1). e005011–e005011. 14 indexed citations
6.
Glez‐Vaz, Javier, Arantza Azpilikueta, Irene Olivera, et al.. (2022). Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. Journal for ImmunoTherapy of Cancer. 10(3). e003532–e003532. 13 indexed citations
7.
Sanmamed, Miguel F., Pedro Berraondo, María E. Rodríguez-Ruiz, & Ignacio Melero. (2022). Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nature Cancer. 3(6). 665–680. 25 indexed citations
8.
Salas‐Benito, Diego, José Luis Perez‐Gracia, Mariano Ponz‐Sarvisé, et al.. (2021). Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discovery. 11(6). 1353–1367. 278 indexed citations breakdown →
9.
Teijeira, Álvaro, Saray Garasa, María C. Ochoa, et al.. (2021). Differential Interleukin‐8 thresholds for chemotaxis and netosis in human neutrophils. European Journal of Immunology. 51(9). 2274–2280. 41 indexed citations
10.
Álvarez, Maite, Carmen Molina, Carlos E. de Andrea, et al.. (2021). Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. Journal for ImmunoTherapy of Cancer. 9(11). e002953–e002953. 29 indexed citations
11.
Minute, Luna, Álvaro Teijeira, Alfonso R. Sánchez-Paulete, et al.. (2020). Cellular cytotoxicity is a form of immunogenic cell death. Journal for ImmunoTherapy of Cancer. 8(1). e000325–e000325. 71 indexed citations
12.
Rodríguez-Ruiz, María E., Inmaculada Rodríguez, Tania Labiano, et al.. (2019). TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies. Molecular Cancer Therapeutics. 18(3). 621–631. 71 indexed citations
13.
Aznar, M. Ángela, Lourdes Planelles, Carmen Molina, et al.. (2019). Immunotherapeutic effects of intratumoral nanoplexed poly I:C. Journal for ImmunoTherapy of Cancer. 7(1). 116–116. 103 indexed citations
14.
Sánchez-Paulete, Alfonso R., Álvaro Teijeira, José I. Quetglas, et al.. (2018). Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virus–Derived Vectors Fosters Dendritic Cell–Mediated T-cell Cross-Priming. Cancer Research. 78(23). 6643–6654. 69 indexed citations
15.
Rodríguez-Ruiz, María E., Inmaculada Rodríguez, Benigno Barbés, et al.. (2017). Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies. Brachytherapy. 16(6). 1246–1251. 35 indexed citations
16.
Rodríguez-Ruiz, María E., Inmaculada Rodríguez, Saray Garasa, et al.. (2016). Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming. Cancer Research. 76(20). 5994–6005. 198 indexed citations
17.
Berraondo, Pedro, María C. Ochoa, María E. Rodríguez-Ruiz, et al.. (2016). Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. Cancer Research. 76(10). 2863–2867. 3 indexed citations
18.
Sanmamed, Miguel F., Inmaculada Rodríguez, Kurt A. Schalper, et al.. (2015). Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2−/−IL2Rγnull Immunodeficient Mice. Cancer Research. 75(17). 3466–3478. 129 indexed citations
19.
Sánchez-Paulete, Alfonso R., Francisco J. Cueto, María Martínez‐López, et al.. (2015). Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discovery. 6(1). 71–79. 362 indexed citations
20.
Sanmamed, Miguel F., Carlos Alfaro, Carmen Oñate, et al.. (2014). Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. Clinical Cancer Research. 20(22). 5697–5707. 204 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liufu Deng Breakdown of academic impact, for papers by Miguel F. Sanmamed Breakdown of academic impact, for papers by Claire Vanpouille‐Box Breakdown of academic impact, for papers by Jitka Fučíková Breakdown of academic impact, for papers by Junzo Hamanishi Breakdown of academic impact, for papers by Ferdy J. Lejeune Breakdown of academic impact, for papers by Mark P. Chao Breakdown of academic impact, for papers by Gunnar Kvalheim Breakdown of academic impact, for papers by Sebastian Kobold Breakdown of academic impact, for papers by Sumit K. Subudhi
Rankless by CCL
2026